| Desirable cell death during anticancer chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 20958322 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The concept of immunogenic chemotherapy that has recently emerged relies upon the capacity of a cytotoxic compound to trigger a cell-death modality. This modality elicits cross-priming by dendritic cells of tumor antigen-specific T cells that will contribute to the tumoricidal activity of the compound and protect the host against relapse. In contrast, most anticancer drugs elicit nonimmunogenic apoptosis that is not accompanied with an immunizing property. This review will discuss some molecular and metabolic changes required at the level of the tumor that must engage key pathways at the level of the host for the induction of Tc1 polarized-protective T cell responses during chemotherapy. We will summarize the immune adjuvants that can boost the immunogenicity of cell death to augment the efficacy of chemotherapy. |
| | |
Authors:
|
Clara Locher; Rosa Conforti; Laetitia Aymeric; Yuting Ma; Takahiro Yamazaki; Sylvie Rusakiewicz; Antoine Tesnière; François Ghiringhelli; Lionel Apetoh; Yannis Morel; Jean-Philippe Girard; Guido Kroemer; Laurence Zitvogel |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1209 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-20 Completed Date: 2010-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 99-108 Citation Subset: IM |
Copyright Information:
|
© 2010 New York Academy of Sciences. |
Affiliation:
|
Institut National de la Santé et de la Recherche Médicale, U1015, Villejuif, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / pharmacology* Apoptosis / drug effects* Cancer Vaccines / administration & dosage Combined Modality Therapy Humans Mice Neoplasms / drug therapy*, immunology, pathology |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Cancer Vaccines |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A role for calreticulin in the pathogenesis of rheumatoid arthritis.
Next Document: Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses.